Evidence map›Paper›PMID 40160342›Full record

ArticleOpen forum infectious diseases2025

Limitations of the MTB/RIF Assay: An Xpert Review of 4 Clinical Cases.

Allison L Haas, Angela Ma, Jonathan Pham, Punam Verma, Uma Malhotra, E Chandler Church, Masahiro Narita, Vincent Escuyer, Salika M Shakir

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allison L HaasDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-2154-4328
Angela MaDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Jonathan PhamDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Punam VermaDepartment of Pathology and Laboratory Medicine, Virginia Mason Medical Center, Seattle, Washington, USA.
Uma MalhotraInfectious Diseases, Virginia Mason Franciscan Health, Seattle, Washington, USA.
E Chandler ChurchDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-3614-5311
Masahiro NaritaSeattle & King County Public Health Department, Seattle, Washington, USA.
Vincent EscuyerNew York State Department of Health, Wadsworth Center, Albany, New York, USA.ORCID https://orcid.org/0000-0002-4435-6709
Salika M ShakirDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0003-4642-8574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current U.S. Centers for Disease Control and Prevention tuberculosis (TB) guidelines recommend molecular testing for initial diagnosis of TB and detection of rifampin resistance to expedite initiation of proper treatment. The Cepheid Xpert MTB/RIF assay can detect members of the

Indexed as

Mycobacterium tuberculosisrapid diagnosticsrifampin resistancerpoB mutationXpert MTB/RIF

Identifiers

PMID40160342
PMCPMC11953001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.